O
Orizuru Therapeutics
IPSC-based regenerative medicine for intractable diseases
About Orizuru Therapeutics
Orizuru Therapeutics is a research and development-driven company focused on induced pluripotent stem cell (iPSC) technology for regenerative medicine. Founded in April 2021 and commencing operations in June 2021, the company was established as a spinout from a joint research program between Takeda Pharmaceutical Company and Kyoto University's Center for iPS Cell Research and Application (CiRA). This 10-year program, known as T-CiRA and led by Professor Shinya Yamanaka, aimed to accelerate the practical application of iPSC technology. Orizuru Therapeutics was formed to advance two promising projects from this collaboration that fell outside of Takeda's primary R&D focus areas.
The company is led by President, Representative Director, and CEO Kenji Nonaka, M.D., Ph.D. Upon its founding, approximately 60 employees, including over a dozen from the T-CiRA program, joined the company, bringing expertise in iPSC technology and pharmaceutical R&D. The establishment of the company was spearheaded by Kyoto University Innovation Capital (KYOTO-iCAP). The company has secured significant funding, raising 6 billion yen in its seed and Series A rounds from investors including Takeda, SMBC Venture Capital, and MUFG Bank, and later completed a Series B round in February 2024 with investors like Japan Growth Capital Investment Corporation and the JDRF T1D Fund.
Orizuru Therapeutics' business is centered on two main pillars. The first is the development of cell therapy products for clinical application. This includes two primary assets: iPSC-derived cardiomyocytes (iCMs or OZTx-556) for treating severe heart failure and iPSC-derived pancreatic islet cells (iPICs or OZTx-410) for brittle type 1 diabetes. The iCM project, led by Dr. Yoshinori Yoshida, focuses on replenishing cardiomyocytes and promoting remuscularization in damaged hearts. The iPIC project, based on research by Dr. Taro Toyoda, aims to create pancreatic islet structures that can physiologically control blood glucose levels. In April 2025, the company announced the completion of the first patient transplantation in a clinical trial for its OZTx-410 product for type 1 diabetes.
The second business area is its Platform Innovation Business, which provides services to support drug discovery and regenerative medicine research. This unit offers contract research, consulting, and on-site support, leveraging the company's expertise in iPSC differentiation, culture, purification, and analysis to assist other organizations. The business model involves seeking co-development or out-licensing opportunities for its main assets, as well as providing outsourced lab services for customers using iPS cells. The company operates out of the Shonan Health Innovation Park in Fujisawa, Japan.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2024 | $22M | $88M | Kyoto University Innovation Capital · SMBC Venture Capital · JDRF T1D Fund · Takeda | ↗ |
| EARLY VCOther financing | Nov 2023 | $17M | $110M | Undisclosed | — |
Growth signals
Latest recorded traffic for Orizuru Therapeutics is 1.2K monthly website visits, down 47.8% over the last three months. Orizuru Therapeutics's team grew 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orizuru Therapeutics in the Fujisawa ecosystem
The Orizuru Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
SMBC Venture Capital
Takeda
Kyoto University Innovation Capital
Nippon Venture Capital
MUFG Bank
Sumitomo Mitsui Finance
Mitsubishi UFJ Financial Group
Medipal
Sumitomo Mitsui Trust Bank
JDRF T1D Fund
MUFG Union Bank
Other known investors1 additional known investor
Kyoto University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orizuru Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orizuru Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










